Page last updated: 2024-11-11

n-(2-amino-5-fluorobenzyl)-4-(n-(pyridine-3-acrylyl)aminomethyl)benzamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID9800555
CHEMBL ID4087968
SCHEMBL ID8057949
MeSH IDM0544456

Synonyms (34)

Synonym
chidamide
chembl4087968 ,
bdbm50242817
S8567
CCG-208658
CS-3554
n-(2-amino-5-fluorophenyl)-4-[[[(e)-3-pyridin-3-ylprop-2-enoyl]amino]methyl]benzamide
SCHEMBL8057949
743420-02-2
WXHHICFWKXDFOW-BJMVGYQFSA-N
n-(2-amino-5-fluorophenyl)-4-[[[1-oxo-3-(3-pyridinyl)-2-propen-1-yl]amino]methyl]benzamide
hdac-in-7
HY-13592
AKOS027339700
benzamide, n-(2-amino-5-fluorophenyl)-4-(((1-oxo-3-(3-pyridinyl)-2-propen-1-yl)amino)methyl)-
1883690-47-8
unii-462284yv3m
462284yv3m ,
n-(2-amino-5-fluorophenyl)-4-(((1-oxo-3-(3-pyridinyl)-2-propen-1-yl)amino)methyl)benzamide
mfcd18382123
(e)-n-(2-amino-5-fluorophenyl)-4-((3-(pyridin-3-yl)acrylamido)methyl)benzamide
tucidinostat(chidamide)
hbi-8000;cs-055
n-(2-amino-5-fluorophenyl)-4-((3-(pyridin-3-yl)acrylamido)methyl)benzamide
tucidinostat (chidamide)
EX-A2209
chidamide; cs055; hbi-8000
AS-47017
Q27075960
A901614
NCGC00263598-10
F11457
DTXSID801348099
n-(2-amino-5-fluorophenyl)-4-{[(2e)-3-(3-pyridinyl)-2-propenamido]methyl}benzamide
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (16)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
PPM1D proteinHomo sapiens (human)Potency7.38760.00529.466132.9993AID1347411
Interferon betaHomo sapiens (human)Potency7.38760.00339.158239.8107AID1347411
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Histone deacetylase 3Homo sapiens (human)IC50 (µMol)30.58020.00040.619610.0000AID1401901; AID1545756; AID1596080; AID1598961; AID1598982; AID1689783
Nuclear receptor corepressor 1Homo sapiens (human)IC50 (µMol)90.11700.00980.07410.2340AID1598961; AID1689783
Cytochrome P450 2C19Homo sapiens (human)IC50 (µMol)7.11000.00002.398310.0000AID1401904
Histone deacetylase 4Homo sapiens (human)IC50 (µMol)1.06000.00061.052610.0000AID1401901; AID1596080; AID1598982
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)32.00000.00091.901410.0000AID1467380
Histone deacetylase 1Homo sapiens (human)IC50 (µMol)22.34830.00010.55439.9000AID1401901; AID1401902; AID1467371; AID1467375; AID1545755; AID1596049; AID1596080; AID1598964; AID1598982; AID1667254; AID1689781; AID1737903
Histone deacetylase 7Homo sapiens (human)IC50 (µMol)1.06000.00071.02609.9000AID1401901; AID1596080; AID1598982
Histone deacetylase 2Homo sapiens (human)IC50 (µMol)3.04410.00010.72219.9700AID1401901; AID1401903; AID1545758; AID1596050; AID1596080; AID1598963; AID1598982; AID1689782; AID1737904
Polyamine deacetylase HDAC10Homo sapiens (human)IC50 (µMol)0.81450.00050.72459.9000AID1401901; AID1545760; AID1596080; AID1598982
Histone deacetylase 11 Homo sapiens (human)IC50 (µMol)1.06000.00030.92989.9000AID1401901; AID1596080; AID1598982
Histone deacetylase 8Homo sapiens (human)IC50 (µMol)207.03600.00070.99479.9000AID1401901; AID1596080; AID1598962; AID1598982; AID1689785
Histone deacetylase 6Homo sapiens (human)IC50 (µMol)146.39290.00000.53769.9000AID1401901; AID1401904; AID1596034; AID1596080; AID1598981; AID1598982; AID1689784
Histone deacetylase 9Homo sapiens (human)IC50 (µMol)1.06000.00050.94139.9000AID1401901; AID1596080; AID1598982
Histone deacetylase 5Homo sapiens (human)IC50 (µMol)1.06000.00070.961010.0000AID1401901; AID1596080; AID1598982
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (242)

Processvia Protein(s)Taxonomy
negative regulation of myotube differentiationHistone deacetylase 3Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 3Homo sapiens (human)
establishment of mitotic spindle orientationHistone deacetylase 3Homo sapiens (human)
in utero embryonic developmentHistone deacetylase 3Homo sapiens (human)
positive regulation of protein phosphorylationHistone deacetylase 3Homo sapiens (human)
chromatin organizationHistone deacetylase 3Homo sapiens (human)
transcription by RNA polymerase IIHistone deacetylase 3Homo sapiens (human)
protein deacetylationHistone deacetylase 3Homo sapiens (human)
regulation of mitotic cell cycleHistone deacetylase 3Homo sapiens (human)
positive regulation of protein ubiquitinationHistone deacetylase 3Homo sapiens (human)
regulation of protein stabilityHistone deacetylase 3Homo sapiens (human)
positive regulation of TOR signalingHistone deacetylase 3Homo sapiens (human)
circadian regulation of gene expressionHistone deacetylase 3Homo sapiens (human)
regulation of multicellular organism growthHistone deacetylase 3Homo sapiens (human)
positive regulation of protein import into nucleusHistone deacetylase 3Homo sapiens (human)
regulation of circadian rhythmHistone deacetylase 3Homo sapiens (human)
negative regulation of apoptotic processHistone deacetylase 3Homo sapiens (human)
negative regulation of DNA-templated transcriptionHistone deacetylase 3Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIHistone deacetylase 3Homo sapiens (human)
negative regulation of JNK cascadeHistone deacetylase 3Homo sapiens (human)
spindle assemblyHistone deacetylase 3Homo sapiens (human)
establishment of skin barrierHistone deacetylase 3Homo sapiens (human)
cellular response to fluid shear stressHistone deacetylase 3Homo sapiens (human)
positive regulation of cold-induced thermogenesisHistone deacetylase 3Homo sapiens (human)
DNA repair-dependent chromatin remodelingHistone deacetylase 3Homo sapiens (human)
cornified envelope assemblyHistone deacetylase 3Homo sapiens (human)
negative regulation of cardiac muscle cell differentiationHistone deacetylase 3Homo sapiens (human)
epigenetic regulation of gene expressionHistone deacetylase 3Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor corepressor 1Homo sapiens (human)
chromatin organizationNuclear receptor corepressor 1Homo sapiens (human)
locomotor rhythmNuclear receptor corepressor 1Homo sapiens (human)
negative regulation of glycolytic processNuclear receptor corepressor 1Homo sapiens (human)
negative regulation of DNA-templated transcriptionNuclear receptor corepressor 1Homo sapiens (human)
negative regulation of fatty acid metabolic processNuclear receptor corepressor 1Homo sapiens (human)
negative regulation of JNK cascadeNuclear receptor corepressor 1Homo sapiens (human)
spindle assemblyNuclear receptor corepressor 1Homo sapiens (human)
negative regulation of androgen receptor signaling pathwayNuclear receptor corepressor 1Homo sapiens (human)
negative regulation of miRNA transcriptionNuclear receptor corepressor 1Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
long-chain fatty acid metabolic processCytochrome P450 2C19Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C19Homo sapiens (human)
steroid metabolic processCytochrome P450 2C19Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C19Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C19Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 4Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 4Homo sapiens (human)
chromatin remodelingHistone deacetylase 4Homo sapiens (human)
protein deacetylationHistone deacetylase 4Homo sapiens (human)
inflammatory responseHistone deacetylase 4Homo sapiens (human)
nervous system developmentHistone deacetylase 4Homo sapiens (human)
positive regulation of cell population proliferationHistone deacetylase 4Homo sapiens (human)
negative regulation of myotube differentiationHistone deacetylase 4Homo sapiens (human)
negative regulation of transcription by competitive promoter bindingHistone deacetylase 4Homo sapiens (human)
response to denervation involved in regulation of muscle adaptationHistone deacetylase 4Homo sapiens (human)
cardiac muscle hypertrophy in response to stressHistone deacetylase 4Homo sapiens (human)
protein sumoylationHistone deacetylase 4Homo sapiens (human)
B cell differentiationHistone deacetylase 4Homo sapiens (human)
positive regulation of protein sumoylationHistone deacetylase 4Homo sapiens (human)
peptidyl-lysine deacetylationHistone deacetylase 4Homo sapiens (human)
B cell activationHistone deacetylase 4Homo sapiens (human)
regulation of protein bindingHistone deacetylase 4Homo sapiens (human)
negative regulation of DNA-binding transcription factor activityHistone deacetylase 4Homo sapiens (human)
negative regulation of gene expression, epigeneticHistone deacetylase 4Homo sapiens (human)
negative regulation of glycolytic processHistone deacetylase 4Homo sapiens (human)
positive regulation of DNA-templated transcriptionHistone deacetylase 4Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIHistone deacetylase 4Homo sapiens (human)
positive regulation of DNA-binding transcription factor activityHistone deacetylase 4Homo sapiens (human)
type I interferon-mediated signaling pathwayHistone deacetylase 4Homo sapiens (human)
response to interleukin-1Histone deacetylase 4Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of myotube differentiationHistone deacetylase 1Homo sapiens (human)
negative regulation of apoptotic processHistone deacetylase 1Homo sapiens (human)
positive regulation of signaling receptor activityHistone deacetylase 1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 1Homo sapiens (human)
chromatin organizationHistone deacetylase 1Homo sapiens (human)
chromatin remodelingHistone deacetylase 1Homo sapiens (human)
DNA methylation-dependent heterochromatin formationHistone deacetylase 1Homo sapiens (human)
regulation of transcription by RNA polymerase IIHistone deacetylase 1Homo sapiens (human)
protein deacetylationHistone deacetylase 1Homo sapiens (human)
endoderm developmentHistone deacetylase 1Homo sapiens (human)
positive regulation of cell population proliferationHistone deacetylase 1Homo sapiens (human)
epidermal cell differentiationHistone deacetylase 1Homo sapiens (human)
positive regulation of gene expressionHistone deacetylase 1Homo sapiens (human)
negative regulation of gene expressionHistone deacetylase 1Homo sapiens (human)
hippocampus developmentHistone deacetylase 1Homo sapiens (human)
neuron differentiationHistone deacetylase 1Homo sapiens (human)
negative regulation of cell migrationHistone deacetylase 1Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayHistone deacetylase 1Homo sapiens (human)
circadian regulation of gene expressionHistone deacetylase 1Homo sapiens (human)
cellular response to platelet-derived growth factor stimulusHistone deacetylase 1Homo sapiens (human)
odontogenesis of dentin-containing toothHistone deacetylase 1Homo sapiens (human)
regulation of cell fate specificationHistone deacetylase 1Homo sapiens (human)
embryonic digit morphogenesisHistone deacetylase 1Homo sapiens (human)
negative regulation of apoptotic processHistone deacetylase 1Homo sapiens (human)
negative regulation of canonical NF-kappaB signal transductionHistone deacetylase 1Homo sapiens (human)
negative regulation by host of viral transcriptionHistone deacetylase 1Homo sapiens (human)
negative regulation of gene expression, epigeneticHistone deacetylase 1Homo sapiens (human)
negative regulation of DNA-templated transcriptionHistone deacetylase 1Homo sapiens (human)
positive regulation of DNA-templated transcriptionHistone deacetylase 1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIHistone deacetylase 1Homo sapiens (human)
positive regulation of smooth muscle cell proliferationHistone deacetylase 1Homo sapiens (human)
oligodendrocyte differentiationHistone deacetylase 1Homo sapiens (human)
positive regulation of oligodendrocyte differentiationHistone deacetylase 1Homo sapiens (human)
negative regulation of androgen receptor signaling pathwayHistone deacetylase 1Homo sapiens (human)
hair follicle placode formationHistone deacetylase 1Homo sapiens (human)
eyelid development in camera-type eyeHistone deacetylase 1Homo sapiens (human)
fungiform papilla formationHistone deacetylase 1Homo sapiens (human)
negative regulation of canonical Wnt signaling pathwayHistone deacetylase 1Homo sapiens (human)
negative regulation of stem cell population maintenanceHistone deacetylase 1Homo sapiens (human)
positive regulation of stem cell population maintenanceHistone deacetylase 1Homo sapiens (human)
regulation of stem cell differentiationHistone deacetylase 1Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathwayHistone deacetylase 1Homo sapiens (human)
heterochromatin formationHistone deacetylase 1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 7Homo sapiens (human)
vasculogenesisHistone deacetylase 7Homo sapiens (human)
chromatin remodelingHistone deacetylase 7Homo sapiens (human)
protein deacetylationHistone deacetylase 7Homo sapiens (human)
cell-cell junction assemblyHistone deacetylase 7Homo sapiens (human)
protein sumoylationHistone deacetylase 7Homo sapiens (human)
negative regulation of interleukin-2 productionHistone deacetylase 7Homo sapiens (human)
negative regulation of osteoblast differentiationHistone deacetylase 7Homo sapiens (human)
regulation of mRNA processingHistone deacetylase 7Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesisHistone deacetylase 7Homo sapiens (human)
negative regulation of non-canonical NF-kappaB signal transductionHistone deacetylase 7Homo sapiens (human)
positive regulation of signaling receptor activityHistone deacetylase 2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 2Homo sapiens (human)
response to amphetamineHistone deacetylase 2Homo sapiens (human)
cardiac muscle hypertrophyHistone deacetylase 2Homo sapiens (human)
chromatin remodelingHistone deacetylase 2Homo sapiens (human)
positive regulation of cell population proliferationHistone deacetylase 2Homo sapiens (human)
response to xenobiotic stimulusHistone deacetylase 2Homo sapiens (human)
epidermal cell differentiationHistone deacetylase 2Homo sapiens (human)
positive regulation of epithelial to mesenchymal transitionHistone deacetylase 2Homo sapiens (human)
negative regulation of transcription by competitive promoter bindingHistone deacetylase 2Homo sapiens (human)
negative regulation of neuron projection developmentHistone deacetylase 2Homo sapiens (human)
dendrite developmentHistone deacetylase 2Homo sapiens (human)
negative regulation of cell migrationHistone deacetylase 2Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayHistone deacetylase 2Homo sapiens (human)
response to caffeineHistone deacetylase 2Homo sapiens (human)
heterochromatin formationHistone deacetylase 2Homo sapiens (human)
response to lipopolysaccharideHistone deacetylase 2Homo sapiens (human)
positive regulation of interleukin-1 productionHistone deacetylase 2Homo sapiens (human)
positive regulation of tumor necrosis factor productionHistone deacetylase 2Homo sapiens (human)
circadian regulation of gene expressionHistone deacetylase 2Homo sapiens (human)
positive regulation of collagen biosynthetic processHistone deacetylase 2Homo sapiens (human)
cellular response to heatHistone deacetylase 2Homo sapiens (human)
response to nicotineHistone deacetylase 2Homo sapiens (human)
protein modification processHistone deacetylase 2Homo sapiens (human)
response to cocaineHistone deacetylase 2Homo sapiens (human)
odontogenesis of dentin-containing toothHistone deacetylase 2Homo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT proteinHistone deacetylase 2Homo sapiens (human)
regulation of cell fate specificationHistone deacetylase 2Homo sapiens (human)
embryonic digit morphogenesisHistone deacetylase 2Homo sapiens (human)
negative regulation of apoptotic processHistone deacetylase 2Homo sapiens (human)
negative regulation of DNA-binding transcription factor activityHistone deacetylase 2Homo sapiens (human)
negative regulation of MHC class II biosynthetic processHistone deacetylase 2Homo sapiens (human)
positive regulation of proteolysisHistone deacetylase 2Homo sapiens (human)
negative regulation of DNA-templated transcriptionHistone deacetylase 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionHistone deacetylase 2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIHistone deacetylase 2Homo sapiens (human)
behavioral response to ethanolHistone deacetylase 2Homo sapiens (human)
positive regulation of oligodendrocyte differentiationHistone deacetylase 2Homo sapiens (human)
response to hyperoxiaHistone deacetylase 2Homo sapiens (human)
hair follicle placode formationHistone deacetylase 2Homo sapiens (human)
negative regulation of dendritic spine developmentHistone deacetylase 2Homo sapiens (human)
eyelid development in camera-type eyeHistone deacetylase 2Homo sapiens (human)
fungiform papilla formationHistone deacetylase 2Homo sapiens (human)
cellular response to hydrogen peroxideHistone deacetylase 2Homo sapiens (human)
cellular response to retinoic acidHistone deacetylase 2Homo sapiens (human)
cellular response to transforming growth factor beta stimulusHistone deacetylase 2Homo sapiens (human)
positive regulation of male mating behaviorHistone deacetylase 2Homo sapiens (human)
negative regulation of stem cell population maintenanceHistone deacetylase 2Homo sapiens (human)
positive regulation of stem cell population maintenanceHistone deacetylase 2Homo sapiens (human)
cellular response to dopamineHistone deacetylase 2Homo sapiens (human)
response to amyloid-betaHistone deacetylase 2Homo sapiens (human)
regulation of stem cell differentiationHistone deacetylase 2Homo sapiens (human)
negative regulation of peptidyl-lysine acetylationHistone deacetylase 2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIPolyamine deacetylase HDAC10Homo sapiens (human)
DNA repairPolyamine deacetylase HDAC10Homo sapiens (human)
chromatin organizationPolyamine deacetylase HDAC10Homo sapiens (human)
regulation of DNA-templated transcriptionPolyamine deacetylase HDAC10Homo sapiens (human)
macroautophagyPolyamine deacetylase HDAC10Homo sapiens (human)
positive regulation of mismatch repairPolyamine deacetylase HDAC10Homo sapiens (human)
homologous recombinationPolyamine deacetylase HDAC10Homo sapiens (human)
negative regulation of DNA-templated transcriptionPolyamine deacetylase HDAC10Homo sapiens (human)
polyamine deacetylationPolyamine deacetylase HDAC10Homo sapiens (human)
spermidine deacetylationPolyamine deacetylase HDAC10Homo sapiens (human)
epigenetic regulation of gene expressionPolyamine deacetylase HDAC10Homo sapiens (human)
chromatin organizationHistone deacetylase 11 Homo sapiens (human)
oligodendrocyte developmentHistone deacetylase 11 Homo sapiens (human)
epigenetic regulation of gene expressionHistone deacetylase 11 Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 8Homo sapiens (human)
chromatin organizationHistone deacetylase 8Homo sapiens (human)
mitotic sister chromatid cohesionHistone deacetylase 8Homo sapiens (human)
negative regulation of protein ubiquitinationHistone deacetylase 8Homo sapiens (human)
regulation of protein stabilityHistone deacetylase 8Homo sapiens (human)
regulation of telomere maintenanceHistone deacetylase 8Homo sapiens (human)
epigenetic regulation of gene expressionHistone deacetylase 8Homo sapiens (human)
polyamine deacetylationHistone deacetylase 6Homo sapiens (human)
spermidine deacetylationHistone deacetylase 6Homo sapiens (human)
positive regulation of signaling receptor activityHistone deacetylase 6Homo sapiens (human)
protein polyubiquitinationHistone deacetylase 6Homo sapiens (human)
response to amphetamineHistone deacetylase 6Homo sapiens (human)
protein deacetylationHistone deacetylase 6Homo sapiens (human)
protein quality control for misfolded or incompletely synthesized proteinsHistone deacetylase 6Homo sapiens (human)
intracellular protein transportHistone deacetylase 6Homo sapiens (human)
autophagyHistone deacetylase 6Homo sapiens (human)
actin filament organizationHistone deacetylase 6Homo sapiens (human)
negative regulation of microtubule depolymerizationHistone deacetylase 6Homo sapiens (human)
regulation of autophagyHistone deacetylase 6Homo sapiens (human)
positive regulation of epithelial cell migrationHistone deacetylase 6Homo sapiens (human)
negative regulation of hydrogen peroxide metabolic processHistone deacetylase 6Homo sapiens (human)
regulation of macroautophagyHistone deacetylase 6Homo sapiens (human)
axonal transport of mitochondrionHistone deacetylase 6Homo sapiens (human)
negative regulation of protein-containing complex assemblyHistone deacetylase 6Homo sapiens (human)
regulation of protein stabilityHistone deacetylase 6Homo sapiens (human)
protein destabilizationHistone deacetylase 6Homo sapiens (human)
lysosome localizationHistone deacetylase 6Homo sapiens (human)
protein-containing complex disassemblyHistone deacetylase 6Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationHistone deacetylase 6Homo sapiens (human)
cellular response to heatHistone deacetylase 6Homo sapiens (human)
peptidyl-lysine deacetylationHistone deacetylase 6Homo sapiens (human)
response to immobilization stressHistone deacetylase 6Homo sapiens (human)
cellular response to topologically incorrect proteinHistone deacetylase 6Homo sapiens (human)
erythrocyte enucleationHistone deacetylase 6Homo sapiens (human)
ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathwayHistone deacetylase 6Homo sapiens (human)
negative regulation of protein-containing complex disassemblyHistone deacetylase 6Homo sapiens (human)
regulation of fat cell differentiationHistone deacetylase 6Homo sapiens (human)
negative regulation of gene expression, epigeneticHistone deacetylase 6Homo sapiens (human)
negative regulation of proteolysisHistone deacetylase 6Homo sapiens (human)
negative regulation of DNA-templated transcriptionHistone deacetylase 6Homo sapiens (human)
collateral sproutingHistone deacetylase 6Homo sapiens (human)
negative regulation of axon extension involved in axon guidanceHistone deacetylase 6Homo sapiens (human)
positive regulation of dendrite morphogenesisHistone deacetylase 6Homo sapiens (human)
negative regulation of oxidoreductase activityHistone deacetylase 6Homo sapiens (human)
response to corticosteroneHistone deacetylase 6Homo sapiens (human)
response to misfolded proteinHistone deacetylase 6Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergicHistone deacetylase 6Homo sapiens (human)
cilium assemblyHistone deacetylase 6Homo sapiens (human)
regulation of microtubule-based movementHistone deacetylase 6Homo sapiens (human)
regulation of androgen receptor signaling pathwayHistone deacetylase 6Homo sapiens (human)
dendritic spine morphogenesisHistone deacetylase 6Homo sapiens (human)
cilium disassemblyHistone deacetylase 6Homo sapiens (human)
parkin-mediated stimulation of mitophagy in response to mitochondrial depolarizationHistone deacetylase 6Homo sapiens (human)
regulation of establishment of protein localizationHistone deacetylase 6Homo sapiens (human)
cellular response to hydrogen peroxideHistone deacetylase 6Homo sapiens (human)
aggresome assemblyHistone deacetylase 6Homo sapiens (human)
polyubiquitinated misfolded protein transportHistone deacetylase 6Homo sapiens (human)
response to growth factorHistone deacetylase 6Homo sapiens (human)
cellular response to misfolded proteinHistone deacetylase 6Homo sapiens (human)
cellular response to parathyroid hormone stimulusHistone deacetylase 6Homo sapiens (human)
response to dexamethasoneHistone deacetylase 6Homo sapiens (human)
tubulin deacetylationHistone deacetylase 6Homo sapiens (human)
positive regulation of tubulin deacetylationHistone deacetylase 6Homo sapiens (human)
positive regulation of cellular response to oxidative stressHistone deacetylase 6Homo sapiens (human)
negative regulation of protein acetylationHistone deacetylase 6Homo sapiens (human)
regulation of autophagy of mitochondrionHistone deacetylase 6Homo sapiens (human)
positive regulation of cholangiocyte proliferationHistone deacetylase 6Homo sapiens (human)
negative regulation of aggrephagyHistone deacetylase 6Homo sapiens (human)
epigenetic regulation of gene expressionHistone deacetylase 6Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 9Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 9Homo sapiens (human)
negative regulation of cytokine productionHistone deacetylase 9Homo sapiens (human)
response to amphetamineHistone deacetylase 9Homo sapiens (human)
inflammatory responseHistone deacetylase 9Homo sapiens (human)
heart developmentHistone deacetylase 9Homo sapiens (human)
neuron differentiationHistone deacetylase 9Homo sapiens (human)
B cell differentiationHistone deacetylase 9Homo sapiens (human)
cellular response to insulin stimulusHistone deacetylase 9Homo sapiens (human)
peptidyl-lysine deacetylationHistone deacetylase 9Homo sapiens (human)
B cell activationHistone deacetylase 9Homo sapiens (human)
cholesterol homeostasisHistone deacetylase 9Homo sapiens (human)
negative regulation of gene expression, epigeneticHistone deacetylase 9Homo sapiens (human)
negative regulation of DNA-templated transcriptionHistone deacetylase 9Homo sapiens (human)
regulation of skeletal muscle fiber developmentHistone deacetylase 9Homo sapiens (human)
regulation of striated muscle cell differentiationHistone deacetylase 9Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesisHistone deacetylase 9Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 5Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 5Homo sapiens (human)
inflammatory responseHistone deacetylase 5Homo sapiens (human)
response to xenobiotic stimulusHistone deacetylase 5Homo sapiens (human)
regulation of myotube differentiationHistone deacetylase 5Homo sapiens (human)
negative regulation of myotube differentiationHistone deacetylase 5Homo sapiens (human)
response to activityHistone deacetylase 5Homo sapiens (human)
neuron differentiationHistone deacetylase 5Homo sapiens (human)
B cell differentiationHistone deacetylase 5Homo sapiens (human)
cellular response to insulin stimulusHistone deacetylase 5Homo sapiens (human)
B cell activationHistone deacetylase 5Homo sapiens (human)
response to cocaineHistone deacetylase 5Homo sapiens (human)
regulation of protein bindingHistone deacetylase 5Homo sapiens (human)
negative regulation of gene expression, epigeneticHistone deacetylase 5Homo sapiens (human)
negative regulation of DNA-templated transcriptionHistone deacetylase 5Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIHistone deacetylase 5Homo sapiens (human)
positive regulation of DNA-binding transcription factor activityHistone deacetylase 5Homo sapiens (human)
cellular response to lipopolysaccharideHistone deacetylase 5Homo sapiens (human)
negative regulation of cell migration involved in sprouting angiogenesisHistone deacetylase 5Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (85)

Processvia Protein(s)Taxonomy
transcription corepressor bindingHistone deacetylase 3Homo sapiens (human)
chromatin bindingHistone deacetylase 3Homo sapiens (human)
transcription corepressor activityHistone deacetylase 3Homo sapiens (human)
histone deacetylase activityHistone deacetylase 3Homo sapiens (human)
protein bindingHistone deacetylase 3Homo sapiens (human)
enzyme bindingHistone deacetylase 3Homo sapiens (human)
cyclin bindingHistone deacetylase 3Homo sapiens (human)
chromatin DNA bindingHistone deacetylase 3Homo sapiens (human)
protein lysine deacetylase activityHistone deacetylase 3Homo sapiens (human)
histone deacetylase bindingHistone deacetylase 3Homo sapiens (human)
NF-kappaB bindingHistone deacetylase 3Homo sapiens (human)
DNA-binding transcription factor bindingHistone deacetylase 3Homo sapiens (human)
protein decrotonylase activityHistone deacetylase 3Homo sapiens (human)
histone decrotonylase activityHistone deacetylase 3Homo sapiens (human)
protein de-2-hydroxyisobutyrylase activityHistone deacetylase 3Homo sapiens (human)
transcription cis-regulatory region bindingNuclear receptor corepressor 1Homo sapiens (human)
transcription corepressor activityNuclear receptor corepressor 1Homo sapiens (human)
protein bindingNuclear receptor corepressor 1Homo sapiens (human)
nuclear receptor bindingNuclear receptor corepressor 1Homo sapiens (human)
histone deacetylase bindingNuclear receptor corepressor 1Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingNuclear receptor corepressor 1Homo sapiens (human)
nuclear thyroid hormone receptor bindingNuclear receptor corepressor 1Homo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
iron ion bindingCytochrome P450 2C19Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxygen bindingCytochrome P450 2C19Homo sapiens (human)
enzyme bindingCytochrome P450 2C19Homo sapiens (human)
heme bindingCytochrome P450 2C19Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
aromatase activityCytochrome P450 2C19Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C19Homo sapiens (human)
transcription cis-regulatory region bindingHistone deacetylase 4Homo sapiens (human)
histone bindingHistone deacetylase 4Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingHistone deacetylase 4Homo sapiens (human)
histone deacetylase activityHistone deacetylase 4Homo sapiens (human)
protein bindingHistone deacetylase 4Homo sapiens (human)
zinc ion bindingHistone deacetylase 4Homo sapiens (human)
SUMO transferase activityHistone deacetylase 4Homo sapiens (human)
potassium ion bindingHistone deacetylase 4Homo sapiens (human)
protein lysine deacetylase activityHistone deacetylase 4Homo sapiens (human)
identical protein bindingHistone deacetylase 4Homo sapiens (human)
histone deacetylase bindingHistone deacetylase 4Homo sapiens (human)
molecular adaptor activityHistone deacetylase 4Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingHistone deacetylase 4Homo sapiens (human)
DNA-binding transcription factor bindingHistone deacetylase 4Homo sapiens (human)
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
nucleosomal DNA bindingHistone deacetylase 1Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingHistone deacetylase 1Homo sapiens (human)
RNA polymerase II core promoter sequence-specific DNA bindingHistone deacetylase 1Homo sapiens (human)
core promoter sequence-specific DNA bindingHistone deacetylase 1Homo sapiens (human)
transcription corepressor bindingHistone deacetylase 1Homo sapiens (human)
p53 bindingHistone deacetylase 1Homo sapiens (human)
transcription corepressor activityHistone deacetylase 1Homo sapiens (human)
histone deacetylase activityHistone deacetylase 1Homo sapiens (human)
protein bindingHistone deacetylase 1Homo sapiens (human)
enzyme bindingHistone deacetylase 1Homo sapiens (human)
protein lysine deacetylase activityHistone deacetylase 1Homo sapiens (human)
Krueppel-associated box domain bindingHistone deacetylase 1Homo sapiens (human)
histone deacetylase bindingHistone deacetylase 1Homo sapiens (human)
NF-kappaB bindingHistone deacetylase 1Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingHistone deacetylase 1Homo sapiens (human)
E-box bindingHistone deacetylase 1Homo sapiens (human)
DNA-binding transcription factor bindingHistone deacetylase 1Homo sapiens (human)
histone decrotonylase activityHistone deacetylase 1Homo sapiens (human)
promoter-specific chromatin bindingHistone deacetylase 1Homo sapiens (human)
chromatin bindingHistone deacetylase 7Homo sapiens (human)
transcription corepressor activityHistone deacetylase 7Homo sapiens (human)
histone deacetylase activityHistone deacetylase 7Homo sapiens (human)
protein kinase C bindingHistone deacetylase 7Homo sapiens (human)
protein bindingHistone deacetylase 7Homo sapiens (human)
SUMO transferase activityHistone deacetylase 7Homo sapiens (human)
protein kinase bindingHistone deacetylase 7Homo sapiens (human)
protein lysine deacetylase activityHistone deacetylase 7Homo sapiens (human)
metal ion bindingHistone deacetylase 7Homo sapiens (human)
14-3-3 protein bindingHistone deacetylase 7Homo sapiens (human)
DNA-binding transcription factor bindingHistone deacetylase 7Homo sapiens (human)
nucleosomal DNA bindingHistone deacetylase 2Homo sapiens (human)
chromatin bindingHistone deacetylase 2Homo sapiens (human)
RNA bindingHistone deacetylase 2Homo sapiens (human)
histone deacetylase activityHistone deacetylase 2Homo sapiens (human)
protein bindingHistone deacetylase 2Homo sapiens (human)
enzyme bindingHistone deacetylase 2Homo sapiens (human)
heat shock protein bindingHistone deacetylase 2Homo sapiens (human)
protein lysine deacetylase activityHistone deacetylase 2Homo sapiens (human)
histone bindingHistone deacetylase 2Homo sapiens (human)
histone deacetylase bindingHistone deacetylase 2Homo sapiens (human)
NF-kappaB bindingHistone deacetylase 2Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingHistone deacetylase 2Homo sapiens (human)
histone decrotonylase activityHistone deacetylase 2Homo sapiens (human)
protein de-2-hydroxyisobutyrylase activityHistone deacetylase 2Homo sapiens (human)
promoter-specific chromatin bindingHistone deacetylase 2Homo sapiens (human)
protein lysine deacetylase activityPolyamine deacetylase HDAC10Homo sapiens (human)
histone deacetylase activityPolyamine deacetylase HDAC10Homo sapiens (human)
protein bindingPolyamine deacetylase HDAC10Homo sapiens (human)
zinc ion bindingPolyamine deacetylase HDAC10Homo sapiens (human)
deacetylase activityPolyamine deacetylase HDAC10Homo sapiens (human)
enzyme bindingPolyamine deacetylase HDAC10Homo sapiens (human)
protein lysine deacetylase activityPolyamine deacetylase HDAC10Homo sapiens (human)
histone deacetylase bindingPolyamine deacetylase HDAC10Homo sapiens (human)
acetylputrescine deacetylase activityPolyamine deacetylase HDAC10Homo sapiens (human)
acetylspermidine deacetylase activityPolyamine deacetylase HDAC10Homo sapiens (human)
histone deacetylase activityHistone deacetylase 11 Homo sapiens (human)
protein bindingHistone deacetylase 11 Homo sapiens (human)
DNA-binding transcription factor bindingHistone deacetylase 11 Homo sapiens (human)
histone deacetylase activityHistone deacetylase 8Homo sapiens (human)
protein bindingHistone deacetylase 8Homo sapiens (human)
Hsp70 protein bindingHistone deacetylase 8Homo sapiens (human)
protein lysine deacetylase activityHistone deacetylase 8Homo sapiens (human)
metal ion bindingHistone deacetylase 8Homo sapiens (human)
Hsp90 protein bindingHistone deacetylase 8Homo sapiens (human)
DNA-binding transcription factor bindingHistone deacetylase 8Homo sapiens (human)
histone decrotonylase activityHistone deacetylase 8Homo sapiens (human)
acetylspermidine deacetylase activityHistone deacetylase 6Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingHistone deacetylase 6Homo sapiens (human)
transcription corepressor bindingHistone deacetylase 6Homo sapiens (human)
actin bindingHistone deacetylase 6Homo sapiens (human)
histone deacetylase activityHistone deacetylase 6Homo sapiens (human)
protein bindingHistone deacetylase 6Homo sapiens (human)
beta-catenin bindingHistone deacetylase 6Homo sapiens (human)
microtubule bindingHistone deacetylase 6Homo sapiens (human)
zinc ion bindingHistone deacetylase 6Homo sapiens (human)
enzyme bindingHistone deacetylase 6Homo sapiens (human)
polyubiquitin modification-dependent protein bindingHistone deacetylase 6Homo sapiens (human)
ubiquitin protein ligase bindingHistone deacetylase 6Homo sapiens (human)
protein lysine deacetylase activityHistone deacetylase 6Homo sapiens (human)
histone deacetylase bindingHistone deacetylase 6Homo sapiens (human)
tubulin deacetylase activityHistone deacetylase 6Homo sapiens (human)
alpha-tubulin bindingHistone deacetylase 6Homo sapiens (human)
ubiquitin bindingHistone deacetylase 6Homo sapiens (human)
tau protein bindingHistone deacetylase 6Homo sapiens (human)
beta-tubulin bindingHistone deacetylase 6Homo sapiens (human)
misfolded protein bindingHistone deacetylase 6Homo sapiens (human)
Hsp90 protein bindingHistone deacetylase 6Homo sapiens (human)
dynein complex bindingHistone deacetylase 6Homo sapiens (human)
transcription factor bindingHistone deacetylase 6Homo sapiens (human)
transcription corepressor activityHistone deacetylase 9Homo sapiens (human)
histone deacetylase activityHistone deacetylase 9Homo sapiens (human)
protein kinase C bindingHistone deacetylase 9Homo sapiens (human)
protein bindingHistone deacetylase 9Homo sapiens (human)
histone H3K14 deacetylase activityHistone deacetylase 9Homo sapiens (human)
histone H3K9 deacetylase activityHistone deacetylase 9Homo sapiens (human)
protein lysine deacetylase activityHistone deacetylase 9Homo sapiens (human)
histone H4K16 deacetylase activityHistone deacetylase 9Homo sapiens (human)
histone deacetylase bindingHistone deacetylase 9Homo sapiens (human)
metal ion bindingHistone deacetylase 9Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingHistone deacetylase 9Homo sapiens (human)
DNA-binding transcription factor bindingHistone deacetylase 9Homo sapiens (human)
transcription cis-regulatory region bindingHistone deacetylase 5Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingHistone deacetylase 5Homo sapiens (human)
transcription corepressor bindingHistone deacetylase 5Homo sapiens (human)
chromatin bindingHistone deacetylase 5Homo sapiens (human)
histone deacetylase activityHistone deacetylase 5Homo sapiens (human)
protein kinase C bindingHistone deacetylase 5Homo sapiens (human)
protein bindingHistone deacetylase 5Homo sapiens (human)
protein lysine deacetylase activityHistone deacetylase 5Homo sapiens (human)
identical protein bindingHistone deacetylase 5Homo sapiens (human)
histone deacetylase bindingHistone deacetylase 5Homo sapiens (human)
metal ion bindingHistone deacetylase 5Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingHistone deacetylase 5Homo sapiens (human)
DNA-binding transcription factor bindingHistone deacetylase 5Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (43)

Processvia Protein(s)Taxonomy
nucleusHistone deacetylase 3Homo sapiens (human)
nucleoplasmHistone deacetylase 3Homo sapiens (human)
cytoplasmHistone deacetylase 3Homo sapiens (human)
Golgi apparatusHistone deacetylase 3Homo sapiens (human)
cytosolHistone deacetylase 3Homo sapiens (human)
plasma membraneHistone deacetylase 3Homo sapiens (human)
mitotic spindleHistone deacetylase 3Homo sapiens (human)
histone deacetylase complexHistone deacetylase 3Homo sapiens (human)
transcription repressor complexHistone deacetylase 3Homo sapiens (human)
nucleusHistone deacetylase 3Homo sapiens (human)
nucleusNuclear receptor corepressor 1Homo sapiens (human)
nucleoplasmNuclear receptor corepressor 1Homo sapiens (human)
cytosolNuclear receptor corepressor 1Homo sapiens (human)
membraneNuclear receptor corepressor 1Homo sapiens (human)
mitotic spindleNuclear receptor corepressor 1Homo sapiens (human)
histone deacetylase complexNuclear receptor corepressor 1Homo sapiens (human)
chromatinNuclear receptor corepressor 1Homo sapiens (human)
transcription repressor complexNuclear receptor corepressor 1Homo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C19Homo sapiens (human)
plasma membraneCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
cytoplasmCytochrome P450 2C19Homo sapiens (human)
nucleusHistone deacetylase 4Homo sapiens (human)
nucleoplasmHistone deacetylase 4Homo sapiens (human)
cytoplasmHistone deacetylase 4Homo sapiens (human)
cytosolHistone deacetylase 4Homo sapiens (human)
nuclear speckHistone deacetylase 4Homo sapiens (human)
histone deacetylase complexHistone deacetylase 4Homo sapiens (human)
chromatinHistone deacetylase 4Homo sapiens (human)
transcription repressor complexHistone deacetylase 4Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
nucleusHistone deacetylase 1Homo sapiens (human)
nucleoplasmHistone deacetylase 1Homo sapiens (human)
cytoplasmHistone deacetylase 1Homo sapiens (human)
cytosolHistone deacetylase 1Homo sapiens (human)
NuRD complexHistone deacetylase 1Homo sapiens (human)
neuronal cell bodyHistone deacetylase 1Homo sapiens (human)
Sin3-type complexHistone deacetylase 1Homo sapiens (human)
histone deacetylase complexHistone deacetylase 1Homo sapiens (human)
chromatinHistone deacetylase 1Homo sapiens (human)
heterochromatinHistone deacetylase 1Homo sapiens (human)
transcription repressor complexHistone deacetylase 1Homo sapiens (human)
protein-containing complexHistone deacetylase 1Homo sapiens (human)
nucleusHistone deacetylase 1Homo sapiens (human)
nucleusHistone deacetylase 7Homo sapiens (human)
nucleoplasmHistone deacetylase 7Homo sapiens (human)
cytoplasmHistone deacetylase 7Homo sapiens (human)
cytosolHistone deacetylase 7Homo sapiens (human)
chromosome, telomeric regionHistone deacetylase 2Homo sapiens (human)
nucleusHistone deacetylase 2Homo sapiens (human)
nucleoplasmHistone deacetylase 2Homo sapiens (human)
cytoplasmHistone deacetylase 2Homo sapiens (human)
NuRD complexHistone deacetylase 2Homo sapiens (human)
Sin3-type complexHistone deacetylase 2Homo sapiens (human)
histone deacetylase complexHistone deacetylase 2Homo sapiens (human)
chromatinHistone deacetylase 2Homo sapiens (human)
protein-containing complexHistone deacetylase 2Homo sapiens (human)
ESC/E(Z) complexHistone deacetylase 2Homo sapiens (human)
nucleusHistone deacetylase 2Homo sapiens (human)
nucleusPolyamine deacetylase HDAC10Homo sapiens (human)
nucleoplasmPolyamine deacetylase HDAC10Homo sapiens (human)
cytoplasmPolyamine deacetylase HDAC10Homo sapiens (human)
cytosolPolyamine deacetylase HDAC10Homo sapiens (human)
intracellular membrane-bounded organellePolyamine deacetylase HDAC10Homo sapiens (human)
histone deacetylase complexPolyamine deacetylase HDAC10Homo sapiens (human)
nucleusHistone deacetylase 11 Homo sapiens (human)
plasma membraneHistone deacetylase 11 Homo sapiens (human)
histone deacetylase complexHistone deacetylase 11 Homo sapiens (human)
nuclear chromosomeHistone deacetylase 8Homo sapiens (human)
nucleusHistone deacetylase 8Homo sapiens (human)
nucleoplasmHistone deacetylase 8Homo sapiens (human)
cytoplasmHistone deacetylase 8Homo sapiens (human)
histone deacetylase complexHistone deacetylase 8Homo sapiens (human)
nucleusHistone deacetylase 8Homo sapiens (human)
nucleusHistone deacetylase 6Homo sapiens (human)
nucleoplasmHistone deacetylase 6Homo sapiens (human)
cytoplasmHistone deacetylase 6Homo sapiens (human)
multivesicular bodyHistone deacetylase 6Homo sapiens (human)
centrosomeHistone deacetylase 6Homo sapiens (human)
cytosolHistone deacetylase 6Homo sapiens (human)
microtubuleHistone deacetylase 6Homo sapiens (human)
caveolaHistone deacetylase 6Homo sapiens (human)
inclusion bodyHistone deacetylase 6Homo sapiens (human)
aggresomeHistone deacetylase 6Homo sapiens (human)
axonHistone deacetylase 6Homo sapiens (human)
dendriteHistone deacetylase 6Homo sapiens (human)
cell leading edgeHistone deacetylase 6Homo sapiens (human)
ciliary basal bodyHistone deacetylase 6Homo sapiens (human)
perikaryonHistone deacetylase 6Homo sapiens (human)
perinuclear region of cytoplasmHistone deacetylase 6Homo sapiens (human)
axon cytoplasmHistone deacetylase 6Homo sapiens (human)
histone deacetylase complexHistone deacetylase 6Homo sapiens (human)
microtubule associated complexHistone deacetylase 6Homo sapiens (human)
nucleusHistone deacetylase 9Homo sapiens (human)
nucleoplasmHistone deacetylase 9Homo sapiens (human)
cytoplasmHistone deacetylase 9Homo sapiens (human)
histone deacetylase complexHistone deacetylase 9Homo sapiens (human)
transcription regulator complexHistone deacetylase 9Homo sapiens (human)
histone methyltransferase complexHistone deacetylase 9Homo sapiens (human)
nucleusHistone deacetylase 5Homo sapiens (human)
nucleoplasmHistone deacetylase 5Homo sapiens (human)
cytoplasmHistone deacetylase 5Homo sapiens (human)
Golgi apparatusHistone deacetylase 5Homo sapiens (human)
cytosolHistone deacetylase 5Homo sapiens (human)
nuclear speckHistone deacetylase 5Homo sapiens (human)
histone deacetylase complexHistone deacetylase 5Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (249)

Assay IDTitleYearJournalArticle
AID1732159Cytotoxicity against human MDA-MB-468 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay2021European journal of medicinal chemistry, Apr-05, Volume: 215CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition.
AID1466016Cell cycle arrest in human A549 cells assessed as accumulation at S phase at 2 umol/L after 48 hrs by propidium iodide staining-based flow cytometry (Rvb = 15.13%)2017European journal of medicinal chemistry, Jul-07, Volume: 134Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
AID1596048Antiproliferative activity against human HCT116 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay2019European journal of medicinal chemistry, Jul-01, Volume: 173Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1737922Induction of apoptosis in human A-375 cells assessed as viable cells at 2 uM incubated for 48 hrs by annexin V-FITC and PI staining based flow cytometry (Rvb = 96.3 %)2020European journal of medicinal chemistry, Jul-15, Volume: 198Design, synthesis and biological evaluation of novel histone deacetylase1/2 (HDAC1/2) and cyclin-dependent Kinase2 (CDK2) dual inhibitors against malignant cancer.
AID1737889Induction of apoptosis in human A-375 cells assessed as early apoptotic cells at 2 uM incubated for 48 hrs by annexin V-FITC and PI staining based flow cytometry (Rvb = 1.34 %)2020European journal of medicinal chemistry, Jul-15, Volume: 198Design, synthesis and biological evaluation of novel histone deacetylase1/2 (HDAC1/2) and cyclin-dependent Kinase2 (CDK2) dual inhibitors against malignant cancer.
AID1598982Inhibition of HDAC in human HeLa cell nuclear extract assessed as decrease in deacetylation of FLUOR DE LYS Green substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins by fluorescence based assay2019European journal of medicinal chemistry, Aug-15, Volume: 176Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity.
AID1545758Inhibition of HDAC2 (unknown origin)2019European journal of medicinal chemistry, Dec-01, Volume: 183Indole: A privileged scaffold for the design of anti-cancer agents.
AID1598974Antiproliferative activity against human HeLa cells assessed as growth inhibition at 2 uM after 72 hrs by CCK-8 assay relative to control2019European journal of medicinal chemistry, Aug-15, Volume: 176Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity.
AID1401900Antiproliferative activity against human HCT116 cells after 72 hrs by CCK-8 assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1689784Inhibition of human recombinant HDAC6 preincubated for 10 mins followed by addition of substrate fluor De Lys SIRT1 deacetylase measured after 30 mins by fluorescent plate reader analysis2020European journal of medicinal chemistry, Mar-01, Volume: 189Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity.
AID1545760Inhibition of HDAC10 (unknown origin)2019European journal of medicinal chemistry, Dec-01, Volume: 183Indole: A privileged scaffold for the design of anti-cancer agents.
AID1596052Selectivity ratio of IC50 for human recombinant His-tagged HDAC6 expressed in baculovirus infected insect cells to IC50 of human recombinant His-tagged HDAC2 (1 to 582 residues) expressed in baculovirus infected insect cells2019European journal of medicinal chemistry, Jul-01, Volume: 173Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1401899Antiproliferative activity against human NCI-H1299 cells after 72 hrs by CCK-8 assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1737900Antiproliferative activity against human HepG2 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay2020European journal of medicinal chemistry, Jul-15, Volume: 198Design, synthesis and biological evaluation of novel histone deacetylase1/2 (HDAC1/2) and cyclin-dependent Kinase2 (CDK2) dual inhibitors against malignant cancer.
AID1737896Inhibition of recombinant human HDAC1 at 10 uM using SIRT1 as substrate incubated for 10 mins followed by substrate addition and measured after 30 mins by fluorescence based assay relative to control2020European journal of medicinal chemistry, Jul-15, Volume: 198Design, synthesis and biological evaluation of novel histone deacetylase1/2 (HDAC1/2) and cyclin-dependent Kinase2 (CDK2) dual inhibitors against malignant cancer.
AID1737935Induction of apoptosis in human HCT-116 cells assessed as late apoptotic cells at 2 uM incubated for 48 hrs by annexin V-FITC and PI staining based flow cytometry (Rvb = 1.88 %)2020European journal of medicinal chemistry, Jul-15, Volume: 198Design, synthesis and biological evaluation of novel histone deacetylase1/2 (HDAC1/2) and cyclin-dependent Kinase2 (CDK2) dual inhibitors against malignant cancer.
AID1598990Induction of apoptosis in human A549 cells assessed as necrotic cells at 0.5 uM after 48 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 0.135%)2019European journal of medicinal chemistry, Aug-15, Volume: 176Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity.
AID1401902Inhibition of human recombinant HDAC1 using Fluor de Lys-Green as substrate preincubated for 5 mins followed by substrate addition and measured after 1 hr by fluorescence assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1598979Antiproliferative activity against human HCT116 cells assessed as decrease in cell viability after 72 hrs by CCK-8 assay2019European journal of medicinal chemistry, Aug-15, Volume: 176Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity.
AID1596061Cell cycle arrest in human SMMC7721 cells assessed as accumulation at G0/G1 phase at 4 uM incubated for 48 hrs by propidium iodide staining based flow cytometry (Rvb=77%)2019European journal of medicinal chemistry, Jul-01, Volume: 173Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1737945Induction of apoptosis in human NCI-H460 cells assessed as viable cells at 2 uM incubated for 48 hrs by annexin V-FITC and PI staining based flow cytometry (Rvb = 90.4 %)2020European journal of medicinal chemistry, Jul-15, Volume: 198Design, synthesis and biological evaluation of novel histone deacetylase1/2 (HDAC1/2) and cyclin-dependent Kinase2 (CDK2) dual inhibitors against malignant cancer.
AID1737643Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
AID1667257Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition by MTT assay
AID1689775Antiproliferative activity against human HCT116 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay2020European journal of medicinal chemistry, Mar-01, Volume: 189Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity.
AID1596065Induction of apoptosis in human SMMC7721 cells assessed as early apoptotic cells at 0.25 uM incubated for 48 hrs by Annexin-V-FITC/propidium iodide staining based flow cytometry (Rvb=2.88%)2019European journal of medicinal chemistry, Jul-01, Volume: 173Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1737641Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
AID1401904Inhibition of human recombinant HDAC6 using Fluor de Lys-Green as substrate preincubated for 5 mins followed by substrate addition and measured after 1 hr by fluorescence assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1598985Inhibition of HDAC in human A549 cells assessed as increase in histone H3K9 acetylation at 1 uM after 12 hrs by Alexa fluor 488/DAPI staining based laser scanning confocal microscopic analysis2019European journal of medicinal chemistry, Aug-15, Volume: 176Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity.
AID1467380Inhibition of recombinant human ERG expressed in HEK293 cells after 9 mins by patch clamp method2017Bioorganic & medicinal chemistry letters, 07-15, Volume: 27, Issue:14
Design, synthesis and biological evaluation of 4-piperazinyl-containing Chidamide derivatives as HDACs inhibitors.
AID1689772Antiproliferative activity against human H460 cells assessed as inhibition of cell growth at 8 uM measured after 72 hrs by CCK-8 assay relative to control2020European journal of medicinal chemistry, Mar-01, Volume: 189Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity.
AID1598972Antiproliferative activity against human HCT116 cells assessed as growth inhibition at 2 uM after 72 hrs by CCK-8 assay relative to control2019European journal of medicinal chemistry, Aug-15, Volume: 176Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity.
AID1401926Cell cycle arrest in human SMMC7721 cells assessed as accumulation of cells at G0/G1 phase at 4 umol/L after 72 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 80.65%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1401911Induction of apoptosis in human SMMC7721 cells assessed as necrotic cells at 0.125 umol/L after 72 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometric analysis (Rvb = 2.48%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1466015Cell cycle arrest in human A549 cells assessed as accumulation at G0/G1 phase at 2 umol/L after 48 hrs by propidium iodide staining-based flow cytometry (Rvb = 75.77%)2017European journal of medicinal chemistry, Jul-07, Volume: 134Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
AID1466008Induction of apoptosis in human A549 cells assessed as late apoptotic cells at 4 umol/L after 48 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometry (Rvb = 2.93%)2017European journal of medicinal chemistry, Jul-07, Volume: 134Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
AID1466007Induction of apoptosis in human A549 cells assessed as early apoptotic cells at 4 umol/L after 48 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometry (Rvb = 3.41%)2017European journal of medicinal chemistry, Jul-07, Volume: 134Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
AID1689781Inhibition of human recombinant HDAC1 preincubated for 10 mins followed by addition of substrate fluor De Lys SIRT1 deacetylase measured after 30 mins by fluorescent plate reader analysis2020European journal of medicinal chemistry, Mar-01, Volume: 189Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity.
AID1596067Induction of apoptosis in human SMMC7721 cells assessed as necrotic cells at 0.25 uM incubated for 48 hrs by Annexin-V-FITC/propidium iodide staining based flow cytometry (Rvb=1.88%)2019European journal of medicinal chemistry, Jul-01, Volume: 173Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1401905Selectivity ratio of IC50 for human recombinant HDAC1 to IC50 for human recombinant HDAC62018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1466012Induction of apoptosis in human A549 cells assessed as late apoptotic cells at 8 umol/L after 48 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometry (Rvb = 2.93%)2017European journal of medicinal chemistry, Jul-07, Volume: 134Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
AID1737897Inhibition of recombinant human N-terminal GST-tagged CDK2/CyclinA2 expressed in baculovirus infected Sf21 cells at 10 uM using histone H1 as substrate incubated for 10 mins by luminescence based assay relative to control2020European journal of medicinal chemistry, Jul-15, Volume: 198Design, synthesis and biological evaluation of novel histone deacetylase1/2 (HDAC1/2) and cyclin-dependent Kinase2 (CDK2) dual inhibitors against malignant cancer.
AID1596075Induction of apoptosis in human SMMC7721 cells assessed as necrotic cells at 4 uM incubated for 48 hrs by Annexin-V-FITC/propidium iodide staining based flow cytometry (Rvb=1.88%)2019European journal of medicinal chemistry, Jul-01, Volume: 173Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1467376Antiproliferative activity against human HCT116 cells after 48 to 72 hrs by MTT assay2017Bioorganic & medicinal chemistry letters, 07-15, Volume: 27, Issue:14
Design, synthesis and biological evaluation of 4-piperazinyl-containing Chidamide derivatives as HDACs inhibitors.
AID1596040Antiproliferative activity against human A549 cells assessed as reduction in cell growth at 2 uM incubated for 72 hrs by CCK-8 assay relative to control2019European journal of medicinal chemistry, Jul-01, Volume: 173Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1599003Cell cycle arrest in human A549 cells assessed as accumulation of cells at G0/G1 phase at 2 uM after 48 hrs by propidium iodide staining-based flow cytometry (Rvb = 73.35%)2019European journal of medicinal chemistry, Aug-15, Volume: 176Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity.
AID1401897Antiproliferative activity against human HeLa cells after 72 hrs by CCK-8 assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1737934Induction of apoptosis in human HCT-116 cells assessed as early apoptotic cells at 2 uM incubated for 48 hrs by annexin V-FITC and PI staining based flow cytometry (Rvb = 4.14 %)2020European journal of medicinal chemistry, Jul-15, Volume: 198Design, synthesis and biological evaluation of novel histone deacetylase1/2 (HDAC1/2) and cyclin-dependent Kinase2 (CDK2) dual inhibitors against malignant cancer.
AID1598969Antiproliferative activity against human A375 cells assessed as growth inhibition at 8 uM after 72 hrs by CCK-8 assay relative to control2019European journal of medicinal chemistry, Aug-15, Volume: 176Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity.
AID1598981Inhibition of recombinant human His tagged HDAC6 expressed in baculovirus infected insect cells assessed as decrease in deacetylation of FLUOR DE LYS SIRT1 substrate by measuring decrease in fluorescence preincubated for 10 mins followed by substrate addi2019European journal of medicinal chemistry, Aug-15, Volume: 176Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity.
AID1465996Antiproliferative activity against human A549 cells after 72 hrs by CCK-8 reagent based assay2017European journal of medicinal chemistry, Jul-07, Volume: 134Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
AID1401923Cell cycle arrest in human SMMC7721 cells assessed as accumulation of cells at G0/G1 phase at 1 umol/L after 72 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 80.65%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1598963Inhibition of recombinant human HDAC2 assessed as decrease in deacetylation of FLUOR DE LYS Green substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins by fluorescence based assay2019European journal of medicinal chemistry, Aug-15, Volume: 176Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity.
AID1667252Inhibition of PARP1 (unknown origin)
AID1465994Inhibition of HDAC in human HeLa cell nuclear extract at 0.625 uM using Fluor de Lys green as substrate after 5 mins by fluorescence assay2017European journal of medicinal chemistry, Jul-07, Volume: 134Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
AID1598967Antiproliferative activity against human A549 cells assessed as growth inhibition at 8 uM after 72 hrs by CCK-8 assay relative to control2019European journal of medicinal chemistry, Aug-15, Volume: 176Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity.
AID1401918Induction of apoptosis in human SMMC7721 cells assessed as late apoptotic cells at 4 umol/L after 72 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometric analysis (Rvb = 0.29%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1598971Antiproliferative activity against human SMMC7721 cells assessed as growth inhibition at 8 uM after 72 hrs by CCK-8 assay relative to control2019European journal of medicinal chemistry, Aug-15, Volume: 176Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity.
AID1737655Cytotoxicity against human K562 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
AID1737923Induction of apoptosis in human A-375 cells assessed as late apoptotic cells at 2 uM incubated for 48 hrs by annexin V-FITC and PI staining based flow cytometry (Rvb = 2.24 %)2020European journal of medicinal chemistry, Jul-15, Volume: 198Design, synthesis and biological evaluation of novel histone deacetylase1/2 (HDAC1/2) and cyclin-dependent Kinase2 (CDK2) dual inhibitors against malignant cancer.
AID1401892Antiproliferative activity against human A375 cells at 8 uM after 72 hrs by CCK-8 assay relative to control2018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1598995Induction of apoptosis in human A549 cells assessed as early apoptotic cells at 2 uM after 48 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 1.19%)2019European journal of medicinal chemistry, Aug-15, Volume: 176Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity.
AID1689792Antimigratory activity against human H460 cells assessed as inhibition of cell migration at 0.5 uM measured after 48 hrs by cell scratch assay2020European journal of medicinal chemistry, Mar-01, Volume: 189Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity.
AID1401898Antiproliferative activity against human SMMC7721 cells after 72 hrs by CCK-8 assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1599001Cell cycle arrest in human A549 cells assessed as accumulation of cells at S phase at 1 uM after 48 hrs by propidium iodide staining-based flow cytometry (Rvb = 12.83%)2019European journal of medicinal chemistry, Aug-15, Volume: 176Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity.
AID1599004Cell cycle arrest in human A549 cells assessed as accumulation of cells at S phase at 2 uM after 48 hrs by propidium iodide staining-based flow cytometry (Rvb = 12.83%)2019European journal of medicinal chemistry, Aug-15, Volume: 176Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity.
AID1596036Antiproliferative activity against human A375 cells assessed as reduction in cell growth at 2 uM incubated for 72 hrs by CCK-8 assay relative to control2019European journal of medicinal chemistry, Jul-01, Volume: 173Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1598962Inhibition of recombinant human HDAC8 assessed as decrease in deacetylation of FLUOR DE LYS substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins by fluorescence based assay2019European journal of medicinal chemistry, Aug-15, Volume: 176Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity.
AID1465995Inhibition of HDAC in human HeLa cell nuclear extract at 5 uM using Fluor de Lys green as substrate after 5 mins by fluorescence assay2017European journal of medicinal chemistry, Jul-07, Volume: 134Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
AID1596073Induction of apoptosis in human SMMC7721 cells assessed as early apoptotic cells at 4 uM incubated for 48 hrs by Annexin-V-FITC/propidium iodide staining based flow cytometry (Rvb=2.88%)2019European journal of medicinal chemistry, Jul-01, Volume: 173Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1599002Cell cycle arrest in human A549 cells assessed as accumulation of cells at G2/M phase at 1 uM after 48 hrs by propidium iodide staining-based flow cytometry (Rvb = 13.62%)2019European journal of medicinal chemistry, Aug-15, Volume: 176Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity.
AID1467378Antiproliferative activity against human K562 cells after 48 to 72 hrs by MTT assay2017Bioorganic & medicinal chemistry letters, 07-15, Volume: 27, Issue:14
Design, synthesis and biological evaluation of 4-piperazinyl-containing Chidamide derivatives as HDACs inhibitors.
AID1737898Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay2020European journal of medicinal chemistry, Jul-15, Volume: 198Design, synthesis and biological evaluation of novel histone deacetylase1/2 (HDAC1/2) and cyclin-dependent Kinase2 (CDK2) dual inhibitors against malignant cancer.
AID1467377Antiproliferative activity against human A549 cells after 48 to 72 hrs by MTT assay2017Bioorganic & medicinal chemistry letters, 07-15, Volume: 27, Issue:14
Design, synthesis and biological evaluation of 4-piperazinyl-containing Chidamide derivatives as HDACs inhibitors.
AID1737640Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
AID1598977Antiproliferative activity against human A375 cells assessed as decrease in cell viability after 72 hrs by CCK-8 assay2019European journal of medicinal chemistry, Aug-15, Volume: 176Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity.
AID1732158Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay2021European journal of medicinal chemistry, Apr-05, Volume: 215CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition.
AID1596074Induction of apoptosis in human SMMC7721 cells assessed as late apoptotic cells at 4 uM incubated for 48 hrs by Annexin-V-FITC/propidium iodide staining based flow cytometry (Rvb=1.73%)2019European journal of medicinal chemistry, Jul-01, Volume: 173Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1732191Cytotoxicity against human HuT78 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay2021European journal of medicinal chemistry, Apr-05, Volume: 215CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition.
AID1596046Antiproliferative activity against human HeLa cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay2019European journal of medicinal chemistry, Jul-01, Volume: 173Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1737959Induction of apoptosis in human HeLa cells assessed as late apoptotic cells at 2 uM incubated for 48 hrs by annexin V-FITC and PI staining based flow cytometry (Rvb = 0.870 %)2020European journal of medicinal chemistry, Jul-15, Volume: 198Design, synthesis and biological evaluation of novel histone deacetylase1/2 (HDAC1/2) and cyclin-dependent Kinase2 (CDK2) dual inhibitors against malignant cancer.
AID1732162Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay2021European journal of medicinal chemistry, Apr-05, Volume: 215CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition.
AID1596056Cell cycle arrest in human SMMC7721 cells assessed as accumulation at S phase at 0.25 uM incubated for 48 hrs by propidium iodide staining based flow cytometry (Rvb=6.83%)2019European journal of medicinal chemistry, Jul-01, Volume: 173Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1598983Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay2019European journal of medicinal chemistry, Aug-15, Volume: 176Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity.
AID1667256Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition by MTT assay
AID1467374Inhibition of recombinant human HDAC1 using a fluorogenic substrate at 10 uM by fluorescence method2017Bioorganic & medicinal chemistry letters, 07-15, Volume: 27, Issue:14
Design, synthesis and biological evaluation of 4-piperazinyl-containing Chidamide derivatives as HDACs inhibitors.
AID1596045Antiproliferative activity against human A375 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay2019European journal of medicinal chemistry, Jul-01, Volume: 173Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1596077Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability after 48 hrs by CCK8 assay2019European journal of medicinal chemistry, Jul-01, Volume: 173Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1689798Induction of apoptosis in human HCT116 cells assessed as number of apoptotic cells at 2 uM incubated for 48 hrs by annexin V-FITC/PI based flow cytometric analysis relative to control2020European journal of medicinal chemistry, Mar-01, Volume: 189Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity.
AID1845909Reversal of HIV-1 latency infected in GFP-fused human J-Lat A2 cells assessed as increase in GFP expression at 4 uM incubated for 3 hrs by flow cytometry2021European journal of medicinal chemistry, Mar-05, Volume: 213HIV latency reversal agents: A potential path for functional cure?
AID1466013Induction of apoptosis in human A549 cells assessed as necrotic cells at 8 umol/L after 48 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometry (Rvb = 0.87%)2017European journal of medicinal chemistry, Jul-07, Volume: 134Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
AID1737642Cytotoxicity in human MDA-MB-468 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
AID1596043Antiproliferative activity against human SMMC7721 cells assessed as reduction in cell growth at 8 uM incubated for 72 hrs by CCK-8 assay relative to control2019European journal of medicinal chemistry, Jul-01, Volume: 173Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1737903Inhibition of recombinant human HDAC1 using SIRT1 as substrate incubated for 10 mins followed by substrate addition and measured after 30 mins by fluorescence based assay2020European journal of medicinal chemistry, Jul-15, Volume: 198Design, synthesis and biological evaluation of novel histone deacetylase1/2 (HDAC1/2) and cyclin-dependent Kinase2 (CDK2) dual inhibitors against malignant cancer.
AID1598975Antiproliferative activity against human HeLa cells assessed as growth inhibition at 8 uM after 72 hrs by CCK-8 assay relative to control2019European journal of medicinal chemistry, Aug-15, Volume: 176Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity.
AID1599007Antimigratory activity against human A549 cells assessed as reduction in cell migration incubated for 48 hrs by scratch wound healing based microscopic analysis2019European journal of medicinal chemistry, Aug-15, Volume: 176Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity.
AID1401916Induction of apoptosis in human SMMC7721 cells assessed as viable cells at 4 umol/L after 72 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometric analysis (Rvb = 97.14%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1689777Antiproliferative activity against human A375 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay2020European journal of medicinal chemistry, Mar-01, Volume: 189Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity.
AID1401919Induction of apoptosis in human SMMC7721 cells assessed as necrotic cells at 4 umol/L after 72 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometric analysis (Rvb = 2.48%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1401907Inhibition of colony formation in human SMMC7721 cells after 7 days by crystal violet staining-based assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1401914Induction of apoptosis in human SMMC7721 cells assessed as late apoptotic cells at 1 umol/L after 72 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometric analysis (Rvb = 0.29%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1401889Antiproliferative activity against human MGC803 cells at 2 uM after 72 hrs by CCK-8 assay relative to control2018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1401890Antiproliferative activity against human MGC803 cells at 8 uM after 72 hrs by CCK-8 assay relative to control2018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1401893Antiproliferative activity against human HeLa cells at 2 uM after 72 hrs by CCK-8 assay relative to control2018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1596057Cell cycle arrest in human SMMC7721 cells assessed as accumulation at G2/M phase at 0.25 uM incubated for 48 hrs by propidium iodide staining based flow cytometry (Rvb=16.17%)2019European journal of medicinal chemistry, Jul-01, Volume: 173Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1737892Antiproliferative activity against human HepG2 cells assessed as reduction in cell growth at 2 uM incubated for 72 hrs by CCK-8 assay relative to control2020European journal of medicinal chemistry, Jul-15, Volume: 198Design, synthesis and biological evaluation of novel histone deacetylase1/2 (HDAC1/2) and cyclin-dependent Kinase2 (CDK2) dual inhibitors against malignant cancer.
AID1596066Induction of apoptosis in human SMMC7721 cells assessed as late apoptotic cells at 0.25 uM incubated for 48 hrs by Annexin-V-FITC/propidium iodide staining based flow cytometry (Rvb=1.73%)2019European journal of medicinal chemistry, Jul-01, Volume: 173Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1599008Inhibition of colony formation in human A549 cells at 0.5 to 2 uM incubated for 10 to 14 days by crystal violet staining based assay2019European journal of medicinal chemistry, Aug-15, Volume: 176Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity.
AID1689773Inhibition of human recombinant HDAC1 at 10 uM preincubated for 10 mins followed by addition of substrate fluor De Lys SIRT1 deacetylase measured after 30 mins by fluorescent plate reader analysis relative to control2020European journal of medicinal chemistry, Mar-01, Volume: 189Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity.
AID1401913Induction of apoptosis in human SMMC7721 cells assessed as early apoptotic cells at 1 umol/L after 72 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometric analysis (Rvb = 0.09%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1466017Cell cycle arrest in human A549 cells assessed as accumulation at G2/M phase at 2 umol/L after 48 hrs by propidium iodide staining-based flow cytometry (Rvb = 9.1%)2017European journal of medicinal chemistry, Jul-07, Volume: 134Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
AID1689779Antiproliferative activity against human SMMC7721 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay2020European journal of medicinal chemistry, Mar-01, Volume: 189Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity.
AID1466019Cell cycle arrest in human A549 cells assessed as accumulation at S phase at 16 umol/L after 48 hrs by propidium iodide staining-based flow cytometry (Rvb = 15.13%)2017European journal of medicinal chemistry, Jul-07, Volume: 134Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
AID1596055Cell cycle arrest in human SMMC7721 cells assessed as accumulation at G0/G1 phase at 0.25 uM incubated for 48 hrs by propidium iodide staining based flow cytometry (Rvb=77%)2019European journal of medicinal chemistry, Jul-01, Volume: 173Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1596064Induction of apoptosis in human SMMC7721 cells assessed as viable cells at 0.25 uM incubated for 48 hrs by Annexin-V-FITC/propidium iodide staining based flow cytometry (Rvb=93.5%)2019European journal of medicinal chemistry, Jul-01, Volume: 173Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1401927Cell cycle arrest in human SMMC7721 cells assessed as accumulation of cells at S phase at 4 umol/L after 72 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 5.21%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1737936Induction of apoptosis in human HCT-116 cells assessed as necrotic cells at 2 uM incubated for 48 hrs by annexin V-FITC and PI staining based flow cytometry (Rvb = 0.124 %)2020European journal of medicinal chemistry, Jul-15, Volume: 198Design, synthesis and biological evaluation of novel histone deacetylase1/2 (HDAC1/2) and cyclin-dependent Kinase2 (CDK2) dual inhibitors against malignant cancer.
AID1737904Inhibition of recombinant human HDAC2 using FLUOR-DE-LYS-Green as substrate incubated for 10 mins followed by substrate addition and measured after 30 mins by fluorescence based assay2020European journal of medicinal chemistry, Jul-15, Volume: 198Design, synthesis and biological evaluation of novel histone deacetylase1/2 (HDAC1/2) and cyclin-dependent Kinase2 (CDK2) dual inhibitors against malignant cancer.
AID1737656Cytotoxicity against human KG -1 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
AID1401922Cell cycle arrest in human SMMC7721 cells assessed as accumulation of cells at G2/M phase at 0.125 umol/L after 72 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 14.14%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1689782Inhibition of human recombinant HDAC2 preincubated for 10 mins followed by addition of substrate fluor De Lys green measured after 30 mins by fluorescent plate reader analysis2020European journal of medicinal chemistry, Mar-01, Volume: 189Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity.
AID1737891Antiproliferative activity against human HCT-116 cells assessed as reduction in cell growth at 8 uM incubated for 72 hrs by CCK-8 assay relative to control2020European journal of medicinal chemistry, Jul-15, Volume: 198Design, synthesis and biological evaluation of novel histone deacetylase1/2 (HDAC1/2) and cyclin-dependent Kinase2 (CDK2) dual inhibitors against malignant cancer.
AID1596062Cell cycle arrest in human SMMC7721 cells assessed as accumulation at S phase at 4 uM incubated for 48 hrs by propidium iodide staining based flow cytometry (Rvb=6.83%)2019European journal of medicinal chemistry, Jul-01, Volume: 173Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1466011Induction of apoptosis in human A549 cells assessed as early apoptotic cells at 8 umol/L after 48 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometry (Rvb = 3.41%)2017European journal of medicinal chemistry, Jul-07, Volume: 134Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
AID1598997Induction of apoptosis in human A549 cells assessed as necrotic cells at 2 uM after 48 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 0.135%)2019European journal of medicinal chemistry, Aug-15, Volume: 176Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity.
AID1598989Induction of apoptosis in human A549 cells assessed as late apoptotic cells at 0.5 uM after 48 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 0.637%)2019European journal of medicinal chemistry, Aug-15, Volume: 176Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity.
AID1737947Induction of apoptosis in human NCI-H460 cells assessed as late apoptotic cells at 2 uM incubated for 48 hrs by annexin V-FITC and PI staining based flow cytometry (Rvb = 6.11 %)2020European journal of medicinal chemistry, Jul-15, Volume: 198Design, synthesis and biological evaluation of novel histone deacetylase1/2 (HDAC1/2) and cyclin-dependent Kinase2 (CDK2) dual inhibitors against malignant cancer.
AID1598996Induction of apoptosis in human A549 cells assessed as late apoptotic cells at 2 uM after 48 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 0.637%)2019European journal of medicinal chemistry, Aug-15, Volume: 176Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity.
AID1465999Antiproliferative activity against human HCT116 cells after 72 hrs by CCK-8 reagent based assay2017European journal of medicinal chemistry, Jul-07, Volume: 134Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
AID1598991Induction of apoptosis in human A549 cells assessed as early apoptotic cells at 1 uM after 48 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 1.19%)2019European journal of medicinal chemistry, Aug-15, Volume: 176Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity.
AID1596042Antiproliferative activity against human HCT116 cells assessed as reduction in cell growth at 2 uM incubated for 72 hrs by CCK-8 assay relative to control2019European journal of medicinal chemistry, Jul-01, Volume: 173Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1598976Antiproliferative activity against human A549 cells assessed as decrease in cell viability after 72 hrs by CCK-8 assay2019European journal of medicinal chemistry, Aug-15, Volume: 176Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity.
AID1596035Antiproliferative activity against human A375 cells assessed as reduction in cell growth at 8 uM incubated for 72 hrs by CCK-8 assay relative to control2019European journal of medicinal chemistry, Jul-01, Volume: 173Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1737894Antiproliferative activity against human H460 cells assessed as reduction in cell growth at 2 uM incubated for 72 hrs by CCK-8 assay relative to control2020European journal of medicinal chemistry, Jul-15, Volume: 198Design, synthesis and biological evaluation of novel histone deacetylase1/2 (HDAC1/2) and cyclin-dependent Kinase2 (CDK2) dual inhibitors against malignant cancer.
AID1596039Antiproliferative activity against human A549 cells assessed as reduction in cell growth at 8 uM incubated for 72 hrs by CCK-8 assay relative to control2019European journal of medicinal chemistry, Jul-01, Volume: 173Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1598966Antiproliferative activity against human A549 cells assessed as growth inhibition at 2 uM after 72 hrs by CCK-8 assay relative to control2019European journal of medicinal chemistry, Aug-15, Volume: 176Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity.
AID1737901Antiproliferative activity against human HCT-116 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay2020European journal of medicinal chemistry, Jul-15, Volume: 198Design, synthesis and biological evaluation of novel histone deacetylase1/2 (HDAC1/2) and cyclin-dependent Kinase2 (CDK2) dual inhibitors against malignant cancer.
AID1599006Antimigratory activity against human A549 cells assessed as reduction in cell migration incubated for 24 hrs by scratch wound healing based microscopic analysis2019European journal of medicinal chemistry, Aug-15, Volume: 176Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity.
AID1410011Reactivation of latent HIV1 infected in human U1 cells assessed as increase in p24 production after 48 hrs by ELISA2018ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3
Elimination of HIV-1 Latently Infected Cells by Gnidimacrin and a Selective HDAC Inhibitor.
AID1401921Cell cycle arrest in human SMMC7721 cells assessed as accumulation of cells at S phase at 0.125 umol/L after 72 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 5.21%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1596038Antiproliferative activity against human HeLa cells assessed as reduction in cell growth at 2 uM incubated for 72 hrs by CCK-8 assay relative to control2019European journal of medicinal chemistry, Jul-01, Volume: 173Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1410012Reactivation of latent HIV1 infected in human U1 cells assessed as increase in p24 production after 48 hrs by ELISA relative to vorinostat2018ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3
Elimination of HIV-1 Latently Infected Cells by Gnidimacrin and a Selective HDAC Inhibitor.
AID1466006Induction of apoptosis in human A549 cells assessed as viable cells at 4 umol/L after 48 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometry (Rvb = 92.79%)2017European journal of medicinal chemistry, Jul-07, Volume: 134Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
AID1689783Inhibition of human recombinant HDAC3/NCOR1 complex preincubated for 10 mins followed by addition of substrate fluor De Lys SIRT1 deacetylase measured after 30 mins by fluorescent plate reader analysis2020European journal of medicinal chemistry, Mar-01, Volume: 189Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity.
AID1598973Antiproliferative activity against human HCT116 cells assessed as growth inhibition at 8 uM after 72 hrs by CCK-8 assay relative to control2019European journal of medicinal chemistry, Aug-15, Volume: 176Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity.
AID1732161Cytotoxicity against human DLD-1 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay2021European journal of medicinal chemistry, Apr-05, Volume: 215CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition.
AID1737899Antiproliferative activity against human A-375 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay2020European journal of medicinal chemistry, Jul-15, Volume: 198Design, synthesis and biological evaluation of novel histone deacetylase1/2 (HDAC1/2) and cyclin-dependent Kinase2 (CDK2) dual inhibitors against malignant cancer.
AID1596041Antiproliferative activity against human HCT116 cells assessed as reduction in cell growth at 8 uM incubated for 72 hrs by CCK-8 assay relative to control2019European journal of medicinal chemistry, Jul-01, Volume: 173Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1732190Cytotoxicity against human HH cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay2021European journal of medicinal chemistry, Apr-05, Volume: 215CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition.
AID1465998Antiproliferative activity against human HepG2 cells after 72 hrs by CCK-8 reagent based assay2017European journal of medicinal chemistry, Jul-07, Volume: 134Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
AID1596072Induction of apoptosis in human SMMC7721 cells assessed as viable cells at 4 uM incubated for 48 hrs by Annexin-V-FITC/propidium iodide staining based flow cytometry (Rvb=93.5%)2019European journal of medicinal chemistry, Jul-01, Volume: 173Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1545756Inhibition of HDAC3 (unknown origin)2019European journal of medicinal chemistry, Dec-01, Volume: 183Indole: A privileged scaffold for the design of anti-cancer agents.
AID1467375Inhibition of recombinant human HDAC1 using a fluorogenic substrate by fluorescence method2017Bioorganic & medicinal chemistry letters, 07-15, Volume: 27, Issue:14
Design, synthesis and biological evaluation of 4-piperazinyl-containing Chidamide derivatives as HDACs inhibitors.
AID1732192Cytotoxicity against human HL-60 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay2021European journal of medicinal chemistry, Apr-05, Volume: 215CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition.
AID1598961Inhibition of recombinant human HDAC3/NCOR1 assessed as decrease in deacetylation of FLUOR DE LYS SIRT1 substrate preincubated for 10 mins followed by substrate addition and and measured after 30 mins by fluorescence based assay2019European journal of medicinal chemistry, Aug-15, Volume: 176Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity.
AID1598978Antiproliferative activity against human SMMC7721 cells assessed as decrease in cell viability after 72 hrs by CCK-8 assay2019European journal of medicinal chemistry, Aug-15, Volume: 176Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity.
AID1737639Cytotoxicity against human HDACi-sensitive YCC-11 cells assessed as reduction in cell growth incubated for 72 hrs by MTS assay
AID1596053Inhibition of cell migration in human SMMC7721 cells at 0.5 uM measured after 48 hrs by microscopic analysis2019European journal of medicinal chemistry, Jul-01, Volume: 173Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1410013Cytotoxicity against human U937 cells assessed as reduction in cell viability after 48 hrs by CellTiter-Glo luminescent cell viability assay2018ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3
Elimination of HIV-1 Latently Infected Cells by Gnidimacrin and a Selective HDAC Inhibitor.
AID1401895Antiproliferative activity against human A375 cells after 72 hrs by CCK-8 assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1466018Cell cycle arrest in human A549 cells assessed as accumulation at G0/G1 phase at 16 umol/L after 48 hrs by propidium iodide staining-based flow cytometry (Rvb = 75.77%)2017European journal of medicinal chemistry, Jul-07, Volume: 134Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
AID1737893Antiproliferative activity against human HepG2 cells assessed as reduction in cell growth at 8 uM incubated for 72 hrs by CCK-8 assay relative to control2020European journal of medicinal chemistry, Jul-15, Volume: 198Design, synthesis and biological evaluation of novel histone deacetylase1/2 (HDAC1/2) and cyclin-dependent Kinase2 (CDK2) dual inhibitors against malignant cancer.
AID1689771Antiproliferative activity against human HCT116 cells assessed as inhibition of cell growth at 8 uM measured after 72 hrs by CCK-8 assay relative to control2020European journal of medicinal chemistry, Mar-01, Volume: 189Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity.
AID1467379Antiproliferative activity against human PC3 cells after 48 to 72 hrs by MTT assay2017Bioorganic & medicinal chemistry letters, 07-15, Volume: 27, Issue:14
Design, synthesis and biological evaluation of 4-piperazinyl-containing Chidamide derivatives as HDACs inhibitors.
AID1401901Inhibition of HDAC in human HeLa cell extract using Fluor de Lys-Green as substrate preincubated for 5 mins followed by substrate addition and measured after 1 hr by fluorescence assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1465997Antiproliferative activity against human MGC803 cells after 72 hrs by CCK-8 reagent based assay2017European journal of medicinal chemistry, Jul-07, Volume: 134Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
AID1737654Cytotoxicity against human HDACi-sensitive YCC3 cells assessed as reduction in cell growth incubated for 72 hrs by MTS assay
AID1596034Inhibition of human recombinant His-tagged HDAC6 expressed in baculovirus infected insect cells using FLUOR DE LYS SIRT1 as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins by fluorescence method2019European journal of medicinal chemistry, Jul-01, Volume: 173Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1545755Inhibition of HDAC1 (unknown origin)2019European journal of medicinal chemistry, Dec-01, Volume: 183Indole: A privileged scaffold for the design of anti-cancer agents.
AID1401903Inhibition of human recombinant HDAC2 using Fluor de Lys-Green as substrate preincubated for 5 mins followed by substrate addition and measured after 1 hr by fluorescence assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1466009Induction of apoptosis in human A549 cells assessed as necrotic cells at 4 umol/L after 48 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometry (Rvb = 0.87%)2017European journal of medicinal chemistry, Jul-07, Volume: 134Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
AID1737933Induction of apoptosis in human HCT-116 cells assessed as viable cells at 2 uM incubated for 48 hrs by annexin V-FITC and PI staining based flow cytometry (Rvb = 93.9 %)2020European journal of medicinal chemistry, Jul-15, Volume: 198Design, synthesis and biological evaluation of novel histone deacetylase1/2 (HDAC1/2) and cyclin-dependent Kinase2 (CDK2) dual inhibitors against malignant cancer.
AID1737957Induction of apoptosis in human HeLa cells assessed as viable cells at 2 uM incubated for 48 hrs by annexin V-FITC and PI staining based flow cytometry (Rvb = 98.5 %)2020European journal of medicinal chemistry, Jul-15, Volume: 198Design, synthesis and biological evaluation of novel histone deacetylase1/2 (HDAC1/2) and cyclin-dependent Kinase2 (CDK2) dual inhibitors against malignant cancer.
AID1689797Induction of apoptosis in human A375 cells assessed as number of apoptotic cells at 2 uM incubated for 48 hrs by annexin V-FITC/PI based flow cytometric analysis relative to control2020European journal of medicinal chemistry, Mar-01, Volume: 189Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity.
AID1596050Inhibition of human recombinant His-tagged HDAC2 (1 to 582 residues) expressed in baculovirus infected insect cells using FLUOR DE LYS Green as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins by fluorescence me2019European journal of medicinal chemistry, Jul-01, Volume: 173Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1596068Induction of apoptosis in human SMMC7721 cells assessed as viable cells at 1 uM incubated for 48 hrs by Annexin-V-FITC/propidium iodide staining based flow cytometry (Rvb=93.5%)2019European journal of medicinal chemistry, Jul-01, Volume: 173Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1737948Induction of apoptosis in human NCI-H460 cells assessed as necrotic cells at 2 uM incubated for 48 hrs by annexin V-FITC and PI staining based flow cytometry (Rvb = 0.632 %)2020European journal of medicinal chemistry, Jul-15, Volume: 198Design, synthesis and biological evaluation of novel histone deacetylase1/2 (HDAC1/2) and cyclin-dependent Kinase2 (CDK2) dual inhibitors against malignant cancer.
AID1598998Cell cycle arrest in human A549 cells assessed as accumulation of cells at S phase at 0.5 uM after 48 hrs by propidium iodide staining-based flow cytometry (Rvb = 12.83%)2019European journal of medicinal chemistry, Aug-15, Volume: 176Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity.
AID1667254Inhibition of HDAC1 (unknown origin)
AID1596051Selectivity ratio of IC50 for human recombinant His-tagged HDAC6 expressed in baculovirus infected insect cells to IC50 of human recombinant His-tagged HDAC1 (482 residues) expressed in baculovirus infected insect cells2019European journal of medicinal chemistry, Jul-01, Volume: 173Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1467371Inhibition of recombinant human HDAC1 expressed in Baculovirus insect cell expression system using [3H]-metabolically labeled acetylated histone substrate after 30 mins by scintillation counting2017Bioorganic & medicinal chemistry letters, 07-15, Volume: 27, Issue:14
Design, synthesis and biological evaluation of 4-piperazinyl-containing Chidamide derivatives as HDACs inhibitors.
AID1401906Selectivity ratio of IC50 for human recombinant HDAC2 to IC50 for human recombinant HDAC62018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1410014Selectivity index, ratio of CC50 for human U937 cells to EC50 for reactivation of latent HIV1 infected in human U1 cells2018ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3
Elimination of HIV-1 Latently Infected Cells by Gnidimacrin and a Selective HDAC Inhibitor.
AID1401915Induction of apoptosis in human SMMC7721 cells assessed as necrotic cells at 1 umol/L after 72 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometric analysis (Rvb = 2.48%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1467373Inhibition of recombinant human HDAC1 using a fluorogenic substrate at 1 uM by fluorescence method2017Bioorganic & medicinal chemistry letters, 07-15, Volume: 27, Issue:14
Design, synthesis and biological evaluation of 4-piperazinyl-containing Chidamide derivatives as HDACs inhibitors.
AID1596070Induction of apoptosis in human SMMC7721 cells assessed as late apoptotic cells at 1 uM incubated for 48 hrs by Annexin-V-FITC/propidium iodide staining based flow cytometry (Rvb=1.73%)2019European journal of medicinal chemistry, Jul-01, Volume: 173Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1596047Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay2019European journal of medicinal chemistry, Jul-01, Volume: 173Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1737890Antiproliferative activity against human HCT-116 cells assessed as reduction in cell growth at 2 uM incubated for 72 hrs by CCK-8 assay relative to control2020European journal of medicinal chemistry, Jul-15, Volume: 198Design, synthesis and biological evaluation of novel histone deacetylase1/2 (HDAC1/2) and cyclin-dependent Kinase2 (CDK2) dual inhibitors against malignant cancer.
AID1599005Cell cycle arrest in human A549 cells assessed as accumulation of cells at G2/M phase at 2 uM after 48 hrs by propidium iodide staining-based flow cytometry (Rvb = 13.62%)2019European journal of medicinal chemistry, Aug-15, Volume: 176Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity.
AID1689811Antiproliferative activity against human HCT116 cells assessed as inhibition of cell growth at 2 uM measured after 72 hrs by CCK-8 assay relative to control2020European journal of medicinal chemistry, Mar-01, Volume: 189Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity.
AID1737960Induction of apoptosis in human HeLa cells assessed as necrotic cells at 2 uM incubated for 48 hrs by annexin V-FITC and PI staining based flow cytometry (Rvb = 0.124 %)2020European journal of medicinal chemistry, Jul-15, Volume: 198Design, synthesis and biological evaluation of novel histone deacetylase1/2 (HDAC1/2) and cyclin-dependent Kinase2 (CDK2) dual inhibitors against malignant cancer.
AID1401896Antiproliferative activity against human MGC803 cells after 72 hrs by CCK-8 assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1401909Induction of apoptosis in human SMMC7721 cells assessed as early apoptotic cells at 0.125 umol/L after 72 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometric analysis (Rvb = 0.09%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1596060Cell cycle arrest in human SMMC7721 cells assessed as accumulation at G2/M phase at 1 uM incubated for 48 hrs by propidium iodide staining based flow cytometry (Rvb=16.17%)2019European journal of medicinal chemistry, Jul-01, Volume: 173Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1596071Induction of apoptosis in human SMMC7721 cells assessed as necrotic cells at 1 uM incubated for 48 hrs by Annexin-V-FITC/propidium iodide staining based flow cytometry (Rvb=1.88%)2019European journal of medicinal chemistry, Jul-01, Volume: 173Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1667255Antiproliferative activity against human K562 cells assessed as cell growth inhibition by MTT assay
AID1596044Antiproliferative activity against human SMMC7721 cells assessed as reduction in cell growth at 2 uM incubated for 72 hrs by CCK-8 assay relative to control2019European journal of medicinal chemistry, Jul-01, Volume: 173Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1596080Inhibition of HDAC in human HeLa cell nuclear extract using fluor-de-lys-green as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins by fluorescence assay2019European journal of medicinal chemistry, Jul-01, Volume: 173Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1732193Cytotoxicity against human KG-1 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay2021European journal of medicinal chemistry, Apr-05, Volume: 215CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition.
AID1596037Antiproliferative activity against human HeLa cells assessed as reduction in cell growth at 8 uM incubated for 72 hrs by CCK-8 assay relative to control2019European journal of medicinal chemistry, Jul-01, Volume: 173Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1598987Induction of apoptosis in human A549 cells assessed as viable cells at 0.5 uM after 48 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 98%)2019European journal of medicinal chemistry, Aug-15, Volume: 176Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity.
AID1689791Antimigratory activity against human A375 cells assessed as inhibition of cell migration at 0.25 uM measured after 48 hrs by cell scratch assay2020European journal of medicinal chemistry, Mar-01, Volume: 189Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity.
AID1401894Antiproliferative activity against human HeLa cells at 8 uM after 72 hrs by CCK-8 assay relative to control2018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1598988Induction of apoptosis in human A549 cells assessed as early apoptotic cells at 0.5 uM after 48 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 1.19%)2019European journal of medicinal chemistry, Aug-15, Volume: 176Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity.
AID1467370Antiproliferative activity against human MRC5 cells after 48 to 72 hrs by MTT assay2017Bioorganic & medicinal chemistry letters, 07-15, Volume: 27, Issue:14
Design, synthesis and biological evaluation of 4-piperazinyl-containing Chidamide derivatives as HDACs inhibitors.
AID1737946Induction of apoptosis in human NCI-H460 cells assessed as early apoptotic cells at 2 uM incubated for 48 hrs by annexin V-FITC and PI staining based flow cytometry (Rvb = 2.88 %)2020European journal of medicinal chemistry, Jul-15, Volume: 198Design, synthesis and biological evaluation of novel histone deacetylase1/2 (HDAC1/2) and cyclin-dependent Kinase2 (CDK2) dual inhibitors against malignant cancer.
AID1689776Antiproliferative activity against human H460 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay2020European journal of medicinal chemistry, Mar-01, Volume: 189Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity.
AID1737657Cytotoxicity against human THP-1 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
AID1401928Cell cycle arrest in human SMMC7721 cells assessed as accumulation of cells at G2/M phase at 4 umol/L after 72 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 14.14%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1401924Cell cycle arrest in human SMMC7721 cells assessed as accumulation of cells at S phase at 1 umol/L after 72 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 5.21%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1596033Antiproliferative activity against human SMMC7721 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay2019European journal of medicinal chemistry, Jul-01, Volume: 173Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1689778Antiproliferative activity against human Hela cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay2020European journal of medicinal chemistry, Mar-01, Volume: 189Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity.
AID1599000Cell cycle arrest in human A549 cells assessed as accumulation of cells at G0/G1 phase at 1 uM after 48 hrs by propidium iodide staining-based flow cytometry (Rvb = 73.35%)2019European journal of medicinal chemistry, Aug-15, Volume: 176Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity.
AID1598964Inhibition of recombinant human His tagged HDAC1 expressed in baculovirus infected insect cells assessed as decrease in deacetylation of FLUOR DE LYS Green substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins by flu2019European journal of medicinal chemistry, Aug-15, Volume: 176Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity.
AID1466020Cell cycle arrest in human A549 cells assessed as accumulation at G2/M phase at 16 umol/L after 48 hrs by propidium iodide staining-based flow cytometry (Rvb = 9.1%)2017European journal of medicinal chemistry, Jul-07, Volume: 134Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
AID1737895Antiproliferative activity against human H460 cells assessed as reduction in cell growth at 8 uM incubated for 72 hrs by CCK-8 assay relative to control2020European journal of medicinal chemistry, Jul-15, Volume: 198Design, synthesis and biological evaluation of novel histone deacetylase1/2 (HDAC1/2) and cyclin-dependent Kinase2 (CDK2) dual inhibitors against malignant cancer.
AID1598970Antiproliferative activity against human SMMC7721 cells assessed as growth inhibition at 2 uM after 72 hrs by CCK-8 assay relative to control2019European journal of medicinal chemistry, Aug-15, Volume: 176Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity.
AID1401910Induction of apoptosis in human SMMC7721 cells assessed as late apoptotic cells at 0.125 umol/L after 72 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometric analysis (Rvb = 0.29%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1596049Inhibition of human recombinant His-tagged HDAC1 (482 residues) expressed in baculovirus infected insect cells using FLUOR DE LYS SIRT1 as substrate incubated for 10 mins followed by substrate addition and measured after 30 mins by fluorescence method2019European journal of medicinal chemistry, Jul-01, Volume: 173Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1466010Induction of apoptosis in human A549 cells assessed as viable cells at 8 umol/L after 48 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometry (Rvb = 92.79%)2017European journal of medicinal chemistry, Jul-07, Volume: 134Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
AID1596059Cell cycle arrest in human SMMC7721 cells assessed as accumulation at S phase at 1 uM incubated for 48 hrs by propidium iodide staining based flow cytometry (Rvb=6.83%)2019European journal of medicinal chemistry, Jul-01, Volume: 173Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1598965Induction of apoptosis in human A549 cells assessed as viable cells at 1 uM after 48 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 98%)2019European journal of medicinal chemistry, Aug-15, Volume: 176Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity.
AID1596058Cell cycle arrest in human SMMC7721 cells assessed as accumulation at G0/G1 phase at 1 uM incubated for 48 hrs by propidium iodide staining based flow cytometry (Rvb=77%)2019European journal of medicinal chemistry, Jul-01, Volume: 173Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1845907Reversal of HIV-1 latency infected in GFP-fused human J-Lat C11 cells assessed as increase in GFP expression at 4 uM incubated for 3 hrs by flow cytometry2021European journal of medicinal chemistry, Mar-05, Volume: 213HIV latency reversal agents: A potential path for functional cure?
AID1689780Cytotoxicity against mouse NIH/3T3 cells incubated for 72 hrs by CCK-8 assay2020European journal of medicinal chemistry, Mar-01, Volume: 189Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity.
AID1737958Induction of apoptosis in human HeLa cells assessed as early apoptotic cells at 2 uM incubated for 48 hrs by annexin V-FITC and PI staining based flow cytometry (Rvb = 0.528 %)2020European journal of medicinal chemistry, Jul-15, Volume: 198Design, synthesis and biological evaluation of novel histone deacetylase1/2 (HDAC1/2) and cyclin-dependent Kinase2 (CDK2) dual inhibitors against malignant cancer.
AID1598994Induction of apoptosis in human A549 cells assessed as viable cells at 2 uM after 48 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 98%)2019European journal of medicinal chemistry, Aug-15, Volume: 176Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity.
AID1401891Antiproliferative activity against human A375 cells at 2 uM after 72 hrs by CCK-8 assay relative to control2018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1732160Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay2021European journal of medicinal chemistry, Apr-05, Volume: 215CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition.
AID1737902Antiproliferative activity against human HeLa cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay2020European journal of medicinal chemistry, Jul-15, Volume: 198Design, synthesis and biological evaluation of novel histone deacetylase1/2 (HDAC1/2) and cyclin-dependent Kinase2 (CDK2) dual inhibitors against malignant cancer.
AID1598984Cell cycle arrest in human A549 cells assessed as accumulation of cells at G0/G1 phase at 0.5 uM after 48 hrs by propidium iodide staining-based flow cytometry (Rvb = 73.35%)2019European journal of medicinal chemistry, Aug-15, Volume: 176Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity.
AID1737924Induction of apoptosis in human A-375 cells assessed as necrotic cells at 2 uM incubated for 48 hrs by annexin V-FITC and PI staining based flow cytometry (Rvb = 0.139 %)2020European journal of medicinal chemistry, Jul-15, Volume: 198Design, synthesis and biological evaluation of novel histone deacetylase1/2 (HDAC1/2) and cyclin-dependent Kinase2 (CDK2) dual inhibitors against malignant cancer.
AID1598992Induction of apoptosis in human A549 cells assessed as late apoptotic cells at 1 uM after 48 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 0.637%)2019European journal of medicinal chemistry, Aug-15, Volume: 176Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity.
AID1466003Antimigratory activity against human A549 cells at 8 umol/L after 48 hrs by scratch assay2017European journal of medicinal chemistry, Jul-07, Volume: 134Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
AID1401925Cell cycle arrest in human SMMC7721 cells assessed as accumulation of cells at G2/M phase at 1 umol/L after 72 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 14.14%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1401917Induction of apoptosis in human SMMC7721 cells assessed as early apoptotic cells at 4 umol/L after 72 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometric analysis (Rvb = 0.09%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1401908Induction of apoptosis in human SMMC7721 cells assessed as viable cells at 0.125 umol/L after 72 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometric analysis (Rvb = 97.14%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1689785Inhibition of human recombinant HDAC8 preincubated for 10 mins followed by substrate addition measured after 30 mins by fluorescent plate reader analysis2020European journal of medicinal chemistry, Mar-01, Volume: 189Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity.
AID1596069Induction of apoptosis in human SMMC7721 cells assessed as early apoptotic cells at 1 uM incubated for 48 hrs by Annexin-V-FITC/propidium iodide staining based flow cytometry (Rvb=2.88%)2019European journal of medicinal chemistry, Jul-01, Volume: 173Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1689812Antiproliferative activity against human H460 cells assessed as inhibition of cell growth at 2 uM measured after 72 hrs by CCK-8 assay relative to control2020European journal of medicinal chemistry, Mar-01, Volume: 189Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity.
AID1596063Cell cycle arrest in human SMMC7721 cells assessed as accumulation at G2/M phase at 4 uM incubated for 48 hrs by propidium iodide staining based flow cytometry (Rvb=16.17%)2019European journal of medicinal chemistry, Jul-01, Volume: 173Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1598999Cell cycle arrest in human A549 cells assessed as accumulation of cells at G2/M phase at 0.5 uM after 48 hrs by propidium iodide staining-based flow cytometry (Rvb = 13.62%)2019European journal of medicinal chemistry, Aug-15, Volume: 176Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity.
AID1598968Antiproliferative activity against human A375 cells assessed as growth inhibition at 2 uM after 72 hrs by CCK-8 assay relative to control2019European journal of medicinal chemistry, Aug-15, Volume: 176Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity.
AID1598993Induction of apoptosis in human A549 cells assessed as necrotic cells at 1 uM after 48 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 0.135%)2019European journal of medicinal chemistry, Aug-15, Volume: 176Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity.
AID1596081Inhibition of colony formation in human SMMC7721 cells at 0.25 to 4 uM incubated for 10 days by crystal violet staining based assay2019European journal of medicinal chemistry, Jul-01, Volume: 173Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1598980Antiproliferative activity against human HeLa cells assessed as decrease in cell viability after 72 hrs by CCK-8 assay2019European journal of medicinal chemistry, Aug-15, Volume: 176Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity.
AID1401912Induction of apoptosis in human SMMC7721 cells assessed as viable cells at 1 umol/L after 72 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometric analysis (Rvb = 97.14%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's7 (46.67)24.3611
2020's8 (53.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.83

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.83 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index4.60 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.83)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (13.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (86.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]